Modifying PGE2–EP4 receptor signalling, like with EP4 receptor antagonists, could be a safer therapy than COX-2 inhibitors for stabilizing plaques in atherosclerosis patients and preventing acute ischemic syndromes. The gene discussed is PTGS2; the disease is atherosclerosis.